East Norriton, PA (PRWEB) February 11, 2009
TGaS® Advisors, a comprehensive benchmarking and advisory services firm focused on pharmaceutical commercial organizations, has launched the next generation of their Commercial Compliance Benchmark (CCB) to help companies navigate in a demanding and evolving regulatory environment.
In developing the new benchmark, TGaS Advisors partnered with Robert Melillo, a practicing attorney with more than 17 years experience who is widely recognized as an authority on compliance. Melillo is a founder of Pharmaceutical Resource Solutions LLC, a leader in pharma compliance management, now part of InVentiv Health.
"Pharma companies face daunting compliance challenges that directly impact marketing priorities and the allocation of resources," Melillo said. "We believe the Commercial Compliance Benchmark will give TGaS Advisors clients what they need to cost effectively develop and maintain the best possible compliance practices."
The new benchmark, which expands and enhances a previous offering from TGaS Advisors, will provide an in-depth, confidential assessment of how companies are handling:
-- Sample Management and other issues under the Prescription Drug Marketing Act (PDMA)
-- Requirements under the Code on Interactions with Healthcare Professionals of the Pharmaceutical Research and Manufacturers of America (PhRMA)
-- State reporting issues
-- Guidelines from the Office of the Inspector General (OIG) of the U.S. Department of Health and Human Services
Participating companies can expect to learn operational best practices in such areas as governance, organizational structure and resources. The new solution, aligned with current regulations, will benchmark more than 400 elements, including how companies typically organize compliance functions and allocate resources. The solution will also help companies identify issues that relate to the regulatory environment, understand how different companies handle these issues and optimize existing technology to meet compliance objectives.
Stephen E. Gerard, Managing Partner, TGaS Advisors, noted that the advisory firm's 2009 Annual State of Pharmaceutical Commercial Operations found compliance to be one of the areas of greatest change for the coming year. "The new benchmark will give clients a thorough understanding of the dynamic regulatory climate and a way to evaluate their own compliance status internally and against their industry peers," said Gerard.
As with other TGaS Advisors solutions, the Commercial Compliance Benchmark will be available exclusively to TGaS Advisors clients on completion of the benchmark, conducted by senior TGaS Advisors Associates and processed through the firm's proprietary Navigator™ (patent pending) methodology. Senior advisors communicate findings exclusively to peer-set participants, providing insights specific to each client and addressing strategy, tactics and optimal practices based on results and industry experience. Presentations also show the broader impact on operational "ecosystems."
About TGaS® Advisors LLC
TGaS Advisors, ranked ninth among health-related companies by the Inc. 500, is the leader in benchmarking and advisory services to the pharmaceutical and biopharmaceutical industry. The TGaS Advisors roster includes nine of the top 10 and the majority of the top 50 pharmaceutical companies with operations in the U.S. market. The firm's benchmarking and advisory services suite of solutions, PharmaStance®, provides clients with a way to measure where they stand with respect to their organizations and answers the question, "How do other pharmaceutical companies do 'it'?" TGaS Advisors is based in East Norriton, Pennsylvania.